Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy

Leuk Lymphoma. 2018 Jul;59(7):1756-1758. doi: 10.1080/10428194.2017.1393667. Epub 2017 Oct 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / diagnosis*
  • Bone Neoplasms / mortality
  • Bone Neoplasms / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Plasmacytoma / diagnosis*
  • Plasmacytoma / mortality
  • Plasmacytoma / therapy*
  • Positron Emission Tomography Computed Tomography
  • Proteasome Inhibitors / administration & dosage
  • Proteasome Inhibitors / adverse effects
  • Proteasome Inhibitors / therapeutic use*
  • Radiotherapy, Intensity-Modulated* / methods
  • Treatment Outcome

Substances

  • Proteasome Inhibitors